North Carolina Physician Sentenced After a Telemedicine Company Used His DEA Registration for More Than 25,000 Buprenorphine Prescriptions

A physician's DEA registration number is the credential that lets a prescription for a controlled substance be filled at a pharmacy. A sentencing in the Western District of North Carolina put a concrete outcome on what can happen when that credential is handed to a telemedicine operation and used to generate prescriptions at volume, without the physician ever meeting the patients whose names appeared on them.

What the Justice Department said Emery did

According to the Justice Department, Dr. Henry Ronald Emery Jr., a physician who lived in Waxhaw, North Carolina, allowed administrative personnel at a company identified as CES to use his Drug Enforcement Administration registration number to issue prescriptions. Prosecutors said CES offered an opioid addiction treatment program that delivered care through telemedicine.

The Justice Department said that arrangement produced more than 25,000 buprenorphine prescriptions issued in Emery's name to patients in multiple states, and that Emery did not have any personal interaction with those patients before the prescriptions went out under his registration. Prosecutors said he received $452,830 from CES over the course of the conspiracy.

The sentence

On August 13, 2026, the court sentenced Emery, 54, to six months in federal prison, to be followed by one year of supervised release, for his role in the conspiracy. The court also ordered him to repay the $452,830 he had received from CES. A prison sentence, once imposed, is a settled outcome rather than an allegation, and the conduct described by prosecutors formed the basis for it.

How the charges arose

The case began years earlier. In an indictment announced in September 2023, Emery was charged with one count of conspiracy to distribute controlled substances outside the bounds of professional medical practice and 11 counts of distribution of controlled substances outside the bounds of professional medical practice. The controlled substance at the center of the case was buprenorphine, a Schedule III drug, and the charged conduct spanned roughly September 2018 through 2022.

The Drug Enforcement Administration's Atlanta Field Division and IRS Criminal Investigation's Charlotte Field Office investigated the matter, and the U.S. Attorney's Office for the Western District of North Carolina prosecuted it.

Why buprenorphine prescribing draws this kind of scrutiny

Buprenorphine is a Schedule III controlled substance and one of the main medications used to treat opioid use disorder. Because it is a controlled substance, a prescription is lawful only when it is issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. The indictment framed the prescriptions in this case as falling outside those bounds, and the DEA registration number is the specific credential that a pharmacy relies on to fill such a prescription.

That is why prosecutors treated the use of Emery's registration, rather than any single prescription, as the core of the conspiracy. When a registration is used to authorize prescriptions detached from any real clinical encounter, the signature that is supposed to certify a legitimate medical judgment is missing.

How this differs from legitimate telehealth for opioid use disorder

Telehealth has become an important channel for treating opioid use disorder, and buprenorphine is central to that care. A case like this one does not establish that online treatment for addiction is unlawful. What prosecutors targeted was the opposite of a genuine clinical relationship: a prescribing credential used to generate prescriptions in volume for patients the physician never evaluated or spoke with.

Legitimate telehealth for opioid use disorder starts with the patient, involves an actual clinical evaluation by a clinician who is responsible for the prescription, and produces prescriptions tied to that evaluation. The conduct at issue here, by contrast, separated the prescription from any such encounter.

What this means for patients

This is general information, not legal or medical advice. For someone seeking treatment for opioid use disorder through an online program, the case is a reminder to look for the markers of real clinical care rather than a reason to avoid telehealth. A few practical signals are worth noticing:

• You can identify the specific clinician responsible for your care and reach that person with questions.
• There is an actual evaluation of your history and situation, not just a form that produces a prescription.
• The program follows up on how the medication is working rather than simply reissuing it.
• Buprenorphine treatment is presented as part of ongoing care, which is how opioid use disorder is generally managed.

The broader enforcement picture

Federal enforcement in telehealth has increasingly focused on the point where a licensed credential meets a high volume operation. Whether the case involves Medicare orders signed for patients a physician never saw or, as here, a DEA registration used to issue thousands of controlled substance prescriptions, the recurring theme is accountability for the professional signature at the center of the transaction. For patients and for the telehealth industry, that signature, and the real clinical judgment it is meant to represent, is exactly where scrutiny now lands.